Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane.
about
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.Adjuvant endocrine therapy in premenopausal women with breast cancer.Predictors of recovery of ovarian function during aromatase inhibitor therapy.Prediction of ovarian function in premenopausal breast cancer patients with amenorrhoea after chemotherapy: a simple clinical scorePost-chemotherapy serum anti-Müllerian hormone level predicts ovarian function recoveryEvaluation of menopausal status among breast cancer patients with chemotherapy-induced amenorrhea
P2860
Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Incidence and predictors of ov ...... from tamoxifen to exemestane.
@en
Incidence and predictors of ovarian function recovery
@nl
type
label
Incidence and predictors of ov ...... from tamoxifen to exemestane.
@en
Incidence and predictors of ovarian function recovery
@nl
prefLabel
Incidence and predictors of ov ...... from tamoxifen to exemestane.
@en
Incidence and predictors of ovarian function recovery
@nl
P2093
P2860
P356
P1433
P1476
Incidence and predictors of ov ...... from tamoxifen to exemestane.
@en
P2093
A Guerrero
F Martínez
M A Climent
P2860
P304
P356
10.1093/ANNONC/MDS464
P577
2012-10-28T00:00:00Z